Twenty-three-valent pneumococcal polysaccharide vaccination (PPSV23; Pneumovax; Merck & Co) did not reduce rates of fatal and nonfatal acute coronary syndrome and ischemic stroke compared with placebo, according to results from a double-blind,…
Pneumococcal Polysaccharide Vaccination Does Not Reduce Rates of Cardiovascular Events | Pharmacy Times
